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outputs include total costs (Singapore dollars (SGD); 1 SGD=0.82 USD), IFIs 
avoided, life-years saved, and incremental cost-effectiveness of posaconazole 
versus fluconazole/ itraconazole. A probabilistic sensitivity analysis (PSA) was 
conducted, where probabilities of IFI, IFI-related death, and 100-day other cause 
mortality were assigned beta distributions from trial data. RESULTS: Total costs 
of prophylaxis with fluconazole/ itraconazole and posaconazole were SGD 4,475 
and SGD 4,999, respectively. Corresponding health outcomes were 0.11 and 0.05 
IFIs and 2.44 and 2.51 life-years. Incremental cost-effectiveness ratios for 
posaconazole were SGD 8,150 per IFI avoided and SGD 7,526 per life-year saved. 
Posaconazole was cost-effective compared to fluconazole/ itraconazole in 94% of 
PSA simulations at a threshold of SGD 80,000 (commonly cited threshold in 
Singapore). CONCLUSIONS: Use of posaconazole in place of fluconazole/ 
itraconazole for prevention of IFIs in a high-risk neutropenic population is cost-
effective at a willingness-to-pay threshold of SGD 80,000 per life-year saved in 
Singapore.  
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OBJECTIVES: To examine the overall incremental cost and survival benefit 
associated with the receipt of second line chemotherapy/biologics (Tx2) among 
elderly Medicare metastatic colon cancer (mCC) patients who had received first 
line chemotherapy/biologics treatment (Tx1). METHODS: Elderly (66+) SEER-
Medicare patients diagnosed with mCC in 2003-2007 were identified and 
followed until death or 12/31/09. The analysis was restricted to patients who 
received any chemotherapy/biologics treatment. Cox regression and partitioned 
least squares regression were utilized to obtain the incremental survival benefit 
and the overall incremental cost associated with the receipt of Tx2 within a five-
year period, respectively. The regressions controlled for patient demographic 
and clinical characteristics including cancer related measures, Charlson 
comorbidity index and proxy for poor performance status. Bootstrapping was 
used to produce 95% confidence intervals (CI). RESULTS: Of the 3,266 elderly 
Medicare mCC who received Tx1, 2,744 (84%) died within the observation period; 
1,440 (44%) received Tx2; 274(8%) received subsequent treatments. The 
incremental survival benefit associated with the receipt of Tx2 was 0.631 years 
(CI: 0.517 − 0.761), and the associated overall incremental cost was $107,027 (CI: 
93,401 − 120,887). The incremental cost-effectiveness ratio for Tx2 was $169,722 
per life year gained (CI: 137,139 − 208,134). CONCLUSIONS: The estimated 
survival benefit of receiving second line chemotherapy/biologics treatment 
ranges from 6 to 9 months, which is consistent with evidence from clinical trials. 
This improved survival was associated with costs that are slightly above 
$100,000.  
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BACKGROUND: Metastatic melanoma (MM) is the deadliest form of skin cancer. 
It’s associated with high mortality with a median overall survival (OS) of 6 to 9 
months. Ipilimumab is the first agent to improve the survival of metastatic 
melanoma patients and to provide long-term benefit to a proportion of patients 
treated within phase II/III studies and expanded access programs. OBJECTIVES: 
To evaluate the cost-effectiveness of ipilimumab in previously treated patients 
for advanced melanoma compared to Best Supportive Care (BSC) from a 
Portuguese national payer perspective. METHODS: A three-state Markov model 
with stable disease, progression and death was developed. The model assumed 
three-week cycles, and the analysis assumed a lifetime time horizon. Costs and 
consequences were discounted at 5%. Patient-level data from the pivotal Phase 
III MDX010-20 trial was used to describe the survival of ipilimumab 3mg/kg and 
BSC (based on the gp100 arm of the trial). Extrapolation methods were used to 
model long-term survival beyond the trial. Clinical practice and resource 
utilization were assessed from a survey of Portuguese oncologists and 
dermatologists. Unit costs were obtained from official sources and outcomes 
were described in life years (LY) gained. One-way and probabilistic SA were also 
undertaken. RESULTS: Ipilimumab was associated with an additional gain of 1.29 
LY when compared to BSC, with an incremental cost-effectiveness ratio of 
€53,579/LY. Results were most sensitive to different survival extrapolation 
assumptions and the treatment cost. Probabilistic SA showed a >95% likelihood 
that ipilimumab is cost-effective at a willingness to pay threshold of €59,000/LY. 
CONCLUSIONS: Ipilimumab offers a significant survival benefit when compared 
with BSC, but at a higher cost. Given the high unmet need, small number of 
advanced melanoma patients and robust sensitivity analyses; it is likely that 
ipilimumab represents a cost-effective treatment for previously treated 
advanced melanoma patients in Portugal.  
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OBJECTIVES: Dosing of chemotherapy regimens using 5-fluorouracil (5-FU) in 
patients with metastatic colorectal cancer (mCRC) is based on body surface area 
(BSA), which has been shown to yield suboptimal plasma 5-FU levels. 
Pharmacokinetic (PK) monitoring of 5-FU shows promise in terms of optimal 
dosing, but its cost-effectiveness is unknown. This study performs a cost-
effectiveness analysis of PK dosing versus BSA dosing of 5-FU among patients 
with mCRC in the UK. METHODS: A decision tree model was used to perform a 
counterfactual simulation of the cost-effectiveness of PK versus BSA dosing of 5-
FU in standard chemotherapy regimens for mCRC in the UK population. All 
patients were assumed to receive first-line therapy for 6 or 12 cycles or until 
progression, after which they received standard post-first-line chemotherapy 
and subsequent palliative care until death. Costs were estimated from the 
perspective of the national health system as payer, were drawn from the 
literature and publically available national unit cost estimates. Effectiveness was 
quality adjusted life years (QALY), with utilities estimated from the literature. 
Discounting was performed at 3% per year. Incremental cost-effectiveness ratios 
comparing PK to BSA dosing were computed for the six most common 
chemotherapy regimens that utilize 5-FU. RESULTS: The average ICER across all 
regimens and weighted by their current distribution was £7,336 per incremental 
QALY gained. The ICER for lifetime discounted incremental cost per incremental 
QALY for PK versus BSA dosing was £3,467 for a FOLFOX4 regimen, £3,594 for a 
FOLFOX6 regimen, £23,428 for FOLFIRI, £3,508 for FOLFOX6 + bevacizumab, 
£21,874 for FOLFIRI + bevacizumab, and £28,862 for a 5-FU + leucovorin 
chemotherapy regimen. CONCLUSIONS: PK dose management of 5-FU based 
chemotherapy regimens for patients with mCRC appears cost-effective from a 
UK national payer perspective. Cost-effectiveness was driven in part by better 
efficacy and reduced adverse events.  
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OBJECTIVES: Metastatic renal cell carcinoma (mRCC) is one of the most common 
adult malignancies. Overall survival (OS) without treatment ranges from 6 to 12 
months and in Ecuador, 269 patients were estimated in 2008 with mRCC. The 
aim of this study was to assess the cost-effectiveness of first-line therapies for 
patients with mRCC from the payer’s perspective over five years. METHODS: 
Cost–effectiveness and cost-utility analyses were developed using a Markov 
model to compare within a six-week cycle: sunitinib (50mg/day, four weeks 
treatment and two week off) versus sorafenib (800mg/day) and bevacizumab 
(10mg/kg bi-weekly) + IFN (9MU every 3 weeks). Model contains 5 health states 
(first-line treatment-no progression-, second-line treatment, palliative care, 
death due to mRCC and death due to other causes). It simulates overall costs, 
progression free-years (PFY), life years gained (LYG) and Quality Adjusted Life 
Years (QALYs) gained. Transition probabilities/utilities were obtained from 
previous published trials. Resource use and costs data was obtained from 
National Ecuadorian Health Formulary (Minister of Health 2012) which includes 
costs data from MoH Centers, IESS, Military Hospital and Police Hospital). Official 
Epi data from the Ecuadorian Institute of Social Security (IESS), Globocan, SOLCA, 
and other local institutions were considered. Both costs and effectiveness were 
discounted using a 5% annual rate. RESULTS: First-line treatment with sunitinib 
showed the highest PFY, LYG and QALYs (1.27; 2.35; 1.56 years, respectively) 
followed by bevacizumab+IFN- (1.11; 2.22; 1.45 years) and sorafenib (0.81; 2.26; 
1.43 years). Expected health care costs related to sunitinib resulted lower: 
US$72,599 versus US$111,286 for sorafenib and US$ 192,208 for 
bevacizumab+IFN. Other costs related with therapy administration, caregivers 
and adverse events were also lower with sunitinib. Probabilistic sensitivity 
analyses showed robustness of these results CONCLUSIONS: Sunitinib is cost–
saving among the new agents for patients with mRCC, achieving higher clinical 
outcomes and lower costs in Ecuador.  
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OBJECTIVES: Prevention of the painful, debilitating and costly skeletal 
complications of BM is an important therapy goal. We aimed to evaluate the 
cost-effectiveness of denosumab (120mg Q4W) versus ZA (4 mg Q4W) in the 
prevention of SRE in prostate cancer patients with BM from the public health 
care setting in Mexico. METHODS: A three-state (on/off treatment and dead) 
lifetime Markov model with 4-week cycles was developed in order to estimate 
the incremental cost-effectiveness ratio (ICER) per SRE avoided. The real-world 
SRE rates in ZA-treated patients were derived from a large commercial database 
and used together with the trial-based treatment effect for denosumab versus 
ZA to estimate the denosumab SRE rate. ZA acquisition cost was gathered from 
local public tenders. Unit cost for medical consultation, drug´s administration 
and laboratory tests were obtained from official lists. Diagnosis-related group 
data were used to assess the costs attributable to SRE. Costs are expressed in 
2012 Mexican pesos. Overall survival was similar between the treatment arms of 
